Switch theme
Sign up to access all valuation multiples
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
2000
341
LTM Revenue $122M
Last FY EBITDA -$57.4M
-$30.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Macrogenics has a last 12-month revenue (LTM) of $122M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Macrogenics achieved revenue of $148M and an EBITDA of -$57.4M.
Macrogenics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Macrogenics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $122M | XXX | $148M | XXX | XXX | XXX |
| Gross Profit | $118M | XXX | $136M | XXX | XXX | XXX |
| Gross Margin | 97% | XXX | 92% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$57.4M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -39% | XXX | XXX | XXX |
| EBIT | -$129M | XXX | -$111M | XXX | XXX | XXX |
| EBIT Margin | -106% | XXX | -75% | XXX | XXX | XXX |
| Net Profit | -$93.2M | XXX | -$67.0M | XXX | XXX | XXX |
| Net Margin | -77% | XXX | -45% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Macrogenics's stock price is $1.
Macrogenics has current market cap of $86.4M, and EV of -$30.2M.
See Macrogenics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$30.2M | $86.4M | XXX | XXX | XXX | XXX | $-1.46 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Macrogenics has market cap of $86.4M and EV of -$30.2M.
Macrogenics's trades at -0.2x EV/Revenue multiple, and 0.5x EV/EBITDA.
Equity research analysts estimate Macrogenics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Macrogenics has a P/E ratio of -0.9x.
See valuation multiples for Macrogenics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $86.4M | XXX | $86.4M | XXX | XXX | XXX |
| EV (current) | -$30.2M | XXX | -$30.2M | XXX | XXX | XXX |
| EV/Revenue | -0.2x | XXX | -0.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 0.5x | XXX | XXX | XXX |
| EV/EBIT | 0.2x | XXX | 0.3x | XXX | XXX | XXX |
| EV/Gross Profit | -0.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.9x | XXX | -1.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMacrogenics's last 12 month revenue growth is -28%
Macrogenics's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.7M for the same period.
Macrogenics's rule of 40 is -24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Macrogenics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Macrogenics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -28% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -39% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -24% | XXX | -67% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 119% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 166% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Macrogenics acquired XXX companies to date.
Last acquisition by Macrogenics was XXXXXXXX, XXXXX XXXXX XXXXXX . Macrogenics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Macrogenics founded? | Macrogenics was founded in 2000. |
| Where is Macrogenics headquartered? | Macrogenics is headquartered in United States of America. |
| How many employees does Macrogenics have? | As of today, Macrogenics has 341 employees. |
| Who is the CEO of Macrogenics? | Macrogenics's CEO is Dr. Scott Koenig, M.D.,PhD. |
| Is Macrogenics publicy listed? | Yes, Macrogenics is a public company listed on NAS. |
| What is the stock symbol of Macrogenics? | Macrogenics trades under MGNX ticker. |
| When did Macrogenics go public? | Macrogenics went public in 2013. |
| Who are competitors of Macrogenics? | Similar companies to Macrogenics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Macrogenics? | Macrogenics's current market cap is $86.4M |
| What is the current revenue of Macrogenics? | Macrogenics's last 12 months revenue is $122M. |
| What is the current revenue growth of Macrogenics? | Macrogenics revenue growth (NTM/LTM) is -28%. |
| What is the current EV/Revenue multiple of Macrogenics? | Current revenue multiple of Macrogenics is -0.2x. |
| Is Macrogenics profitable? | Yes, Macrogenics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
